Literature DB >> 29357192

Negative regulation of type I IFN signaling.

Kei-Ichiro Arimoto1, Sayuri Miyauchi1, Samuel A Stoner1, Jun-Bao Fan1, Dong-Er Zhang1,2,3.   

Abstract

Type I IFNs (α, β, and others) are a family of cytokines that are produced in physiological conditions as well as in response to the activation of pattern recognition receptors. They are critically important in controlling the host innate and adaptive immune response to viral and some bacterial infections, cancer, and other inflammatory stimuli. However, dysregulation of type I IFN production or response can contribute to immune pathologies termed "interferonopathies", pointing to the importance of balanced activating signals with tightly regulated mechanisms of tuning this signaling. Here, we summarize the recent advances of how type I IFN production and response are controlled at multiple levels of the type I IFN signaling cascade. ©2018 Society for Leukocyte Biology.

Entities:  

Keywords:  negative regulation; type I interferon

Year:  2018        PMID: 29357192     DOI: 10.1002/JLB.2MIR0817-342R

Source DB:  PubMed          Journal:  J Leukoc Biol        ISSN: 0741-5400            Impact factor:   4.962


  34 in total

1.  CCR2 Signaling Selectively Regulates IFN-α: Role of β-Arrestin 2 in IFNAR1 Internalization.

Authors:  Dionna W Williams; Lauren C Askew; Elonna Jones; Janice E Clements
Journal:  J Immunol       Date:  2018-11-30       Impact factor: 5.422

2.  The probacterial effect of type I interferon signaling requires its own negative regulator USP18.

Authors:  Namir Shaabani; Nadine Honke; Nhan Nguyen; Zhe Huang; Kei-Ichiro Arimoto; Daniel Lazar; Taylor K Loe; Karl S Lang; Marco Prinz; Klaus-Peter Knobeloch; Dong-Er Zhang; John R Teijaro
Journal:  Sci Immunol       Date:  2018-09-28

Review 3.  Too much of a good thing: Detrimental effects of interferon.

Authors:  Nancy C Reich
Journal:  Semin Immunol       Date:  2019-06       Impact factor: 11.130

Review 4.  The IFN-λ4 Conundrum: When a Good Interferon Goes Bad.

Authors:  Olusegun O Onabajo; Brian Muchmore; Ludmila Prokunina-Olsson
Journal:  J Interferon Cytokine Res       Date:  2019-06-26       Impact factor: 2.607

5.  Rhinovirus-Induced SIRT-1 via TLR2 Regulates Subsequent Type I and Type III IFN Responses in Airway Epithelial Cells.

Authors:  Nathaniel Xander; Hymavathi Reddy Vari; Rewees Eskandar; Wuyan Li; Sudhir Bolla; Nathaniel Marchetti; Umadevi S Sajjan
Journal:  J Immunol       Date:  2019-09-23       Impact factor: 5.422

6.  Attenuation of interferon regulatory factor 7 activity in local infectious sites of trachea and lung for preventing the development of acute lung injury caused by influenza A virus.

Authors:  Lei Yang; Liqun Tu; Peiyan Zhao; Ying Wang; Shengnan Wang; Wenting Lu; Yangyang Wang; Xin Li; Yongli Yu; Shucheng Hua; Liying Wang
Journal:  Immunology       Date:  2019-02-27       Impact factor: 7.397

7.  Selective Interferon Responses of Intestinal Epithelial Cells Minimize Tumor Necrosis Factor Alpha Cytotoxicity.

Authors:  Jacob A Van Winkle; David A Constant; Lena Li; Timothy J Nice
Journal:  J Virol       Date:  2020-10-14       Impact factor: 5.103

8.  Heterogeneity of IFN-Mediated Responses and Tumor Immunogenicity in Patients with Cervical Cancer Receiving Concurrent Chemoradiotherapy.

Authors:  Jianzhou Chen; Chuangzhen Chen; Yizhou Zhan; Li Zhou; Jie Chen; Qingxin Cai; Yanxuan Wu; Zhihan Sui; Chengbing Zeng; Xiaolong Wei; Ruth Muschel
Journal:  Clin Cancer Res       Date:  2021-03-25       Impact factor: 12.531

9.  ETV7 limits antiviral gene expression and control of influenza viruses.

Authors:  Heather M Froggatt; Alfred T Harding; Ryan R Chaparian; Nicholas S Heaton
Journal:  Sci Signal       Date:  2021-07-13       Impact factor: 8.192

Review 10.  Homozygous Co-Deletion of Type I Interferons and CDKN2A Genes in Thoracic Cancers: Potential Consequences for Therapy.

Authors:  Marion Grard; Camille Chatelain; Tiphaine Delaunay; Elvire Pons-Tostivint; Jaafar Bennouna; Jean-François Fonteneau
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.